Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04920617 · ClinicalTrials.gov registry record · Phase 2
DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
A Phase 2 study of Refractory Diffuse Large B-Cell Lymphoma and Relapsed Diffuse Large B-cell Lymphoma, sponsored by ImmunoVaccine Technologies, Inc. (IMV Inc.).
- Recruiting
- Registry status
- Phase 2
- Development phase
- 102
- Enrollment target
- 20
- Study locations
NCT04920617: Recruiting Phase 2 study of Refractory Diffuse Large B-Cell Lymphoma and Relapsed Diffuse Large B-cell Lymphoma, sponsored by ImmunoVaccine Technologies, Inc. (IMV Inc.).
NCT04920617 is a Phase 2 study of Refractory Diffuse Large B-Cell Lymphoma and Relapsed Diffuse Large B-cell Lymphoma that is actively recruiting participants, run by ImmunoVaccine Technologies, Inc. (IMV Inc.). The registered enrollment target is 102 participants, above the 61-participant average among 37 other Refractory Diffuse Large B-Cell Lymphoma trials with a reported enrollment target (67% higher). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04920617, a Phase 2 study of Refractory Diffuse Large B-Cell Lymphoma and Relapsed Diffuse Large B-cell Lymphoma, is actively recruiting participants, sponsored by ImmunoVaccine Technologies, Inc. (IMV Inc.).
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 102 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 2b, randomized, open label study to assess the safety and efficacy of DPX-Survivac and pembrolizumab, with and without low-dose cyclophosphamide (CPA) in subjects with relapsed or refractory DLBCL.
Primary Outcome
Centrally evaluated using Lugano (2014)
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG DPX-Survivac
- DRUG CPA
Study Locations (20)
Florida
- Boca Raton Regional Hospital - Boca Raton
- BRCR Medical Center Inc. - Hollywood
- BRCR Medical Center Inc. - Plantation
- Comprehensive Hematology and Oncology - St. Petersburg
Ohio
- Gabrail Cancer Center Research - Canton
- University of Toledo Medical Center - Toledo
- Toledo Clinic Cancer Center - Toledo
Pennsylvania
- Allegheny Health Network (AHN) West Penn Hospital - Pittsburgh
- Reading Hospital - McGlinn Cancer Institute - West Reading
Victoria
- Epworth Freemasons Hospital - Melbourne
- Box Hill Hospital - Melbourne
California
- Compassionate Cancer Care Medical Group - Fountain Valley
Georgia
- Blood and Marrow Transplant Group of Georgia - Atlanta
Indiana
- Indiana University Health Melvin and Bren Simon Cancer Center - Indianapolis
Louisiana
- Tulane Cancer Center Office of Clinical Research - New Orleans
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 102 participants |
| Start Date | 2021-06-18 |
| Est. Completion | 2025-04 |
| Phase | Phase 2 |
What NCT04920617 shows while recruiting
NCT04920617 is an interventional study that assigns participants to a tested intervention. The registered 102 participants enrollment target is mid-sized for trials with a published cap, above the 61-participant average among 37 other Refractory Diffuse Large B-Cell Lymphoma trials with a reported enrollment target (67% higher).
The record links to 2 conditions, with Refractory Diffuse Large B-Cell Lymphoma appearing as the primary indexed condition, and to 3 interventions - of which Pembrolizumab is the first listed.
NCT04920617 names 20 study sites across 13 states, led by Florida, Ohio, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT04920617 about?
NCT04920617 is a clinical study titled "DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma". This is a Phase 2b, randomized, open label study to assess the safety and efficacy of DPX-Survivac and pembrolizumab, with and without low-dose cyclophosphamide (CPA) in subjects with relapsed or refractory DLBCL.
What is the current status of trial NCT04920617?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 102 participants. The study started on 2021-06-18. Estimated completion is 2025-04.
What conditions does trial NCT04920617 study?
This clinical trial studies the following conditions: Refractory Diffuse Large B-Cell Lymphoma, Relapsed Diffuse Large B-cell Lymphoma.
What interventions are being tested in trial NCT04920617?
The interventions under investigation include: Pembrolizumab (DRUG), DPX-Survivac (DRUG), CPA (DRUG).
Who is sponsoring clinical trial NCT04920617?
This trial is sponsored by ImmunoVaccine Technologies, Inc. (IMV Inc.), which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04920617 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Indiana, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Refractory Diffuse Large B-Cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04920617's enrollment target sits among peer trials
102 5th of 37 higher than 33 of 37 other Refractory Diffuse Large B-Cell Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Refractory Diffuse Large B-Cell Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
RECRUITING · Phase 2
-
Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T
RECRUITING · Phase 2
-
Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
RECRUITING · Phase 2
-
Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antigen Receptor T-cell Therapy
RECRUITING · Phase 2
-
Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Exposure to High-Risk Antibiotics Who Are Receiving Chimeric Antigen Receptor T Cells
RECRUITING · Phase 2
-
Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03704662 · 102 participants · NA
Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable or Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma
- NCT04174742 · 102 participants
Self Reported Pain in Women While Undergoing Treatment for Non-metastatic Breast Cancer
- NCT04275362 · 102 participants
Gait Analysis of a Lateral-Pivot Design Total Knee Replacement
- NCT04541082 · 102 participants · Phase 1
Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI